Kenya BioVax Institute Limited and the US Pharmacopeia (USP) formalized their collaboration through the signing of a Memorandum of Understanding on February 14, 2026. Signed on the margins of the hashtag#AUSummit, the partnership is a milestone in strengthening Kenya’s biomanufacturing ecosystem by advancing quality assurance systems, regulatory standards, and technical expertise to support the production of safe, reliable, and locally manufactured vaccines and biologics.
This collaboration reinforces Kenya’s commitment to health security, sustainable industrial growth, and expanding regional access to high-quality health products.